Moleculin Biotech, Inc., ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it ...

Am J Health Syst Pharm. 2006;63(11):1022-1028. Q: How can potential medication errors be minimized when dispensing investigational drugs to better ensure patient safety and improve adherence to ...

today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) to initiate a clinical study of the company’s investigational UKidney ...

SANTA ANA, Calif. - NKGen Biotech, Inc. (NASDAQ: NKGN), a clinical-stage biotechnology company with a current market ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application ...

Please provide your email address to receive an email when new articles are posted on ... episodes and nighttime blood pressure (BP). The drug’s safety profile in this specific patient ...

The investigational drug, called PMD-026, is currently in phase 2 clinical trials ... “These patients have no effective medical therapies, so we hope this new drug will help fill that gap in clinical ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

These programmes are a beacon, offering routes to explore investigational drugs outside the typical confines of clinical trials. 2 They stand as lifelines for those who have journeyed through ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug ...